KING ABDULAZIZ UNIVERSITY

Temozolomide Plus Radiation Improves Survival in Grade II Gliomas: Phase 3 Trial

6 months ago

• A phase 3 trial (ECOG-ACRIN E3F05) demonstrates that adding temozolomide to radiation therapy significantly improves overall survival (OS) in patients with grade II gliomas. • The study reveals a 70% 10-year survival rate with the combined treatment versus 47% with radiation alone, marking a clinically significant improvement. • Progression-free survival (PFS) did not significantly differ between the treatment arms, but the OS benefit was consistent across patients with and without 1p/19q codeletions. • Temozolomide presents a less toxic and more convenient alternative to PCV chemotherapy, offering a valuable option for managing grade II gliomas.